changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
* BTG IM are not responsible for Noteworthy News content
15 Jun 2018
The one-year results of the ACCESS PTS trial have shown that EKOS therapy (BTG) statistically improves post-thrombotic syndrome scores and sequelae as well as quality of life outcomes.
28 Apr 2018
BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.
25 Aug 2016
BTG International Canada Inc. announced it received approval for its drug-eluding device, the DC Bead LUMI, from Health Canada. The bead is the first commercially available product for patients with hepatocellular carcinoma and colorectal cancer metastasized to the liver.
17 May 2016
BTG, the technology healthcare company that develops products to shrink liver tumours and zap blood clots, has enjoyed a “coming of age”, its boss has said, after revealing that profits more than doubled last year.
6 May 2016
BTG Group is buying a US company that develops medical devices which kill tumours by freezing them, as it looks to further boost its presence in the world of interventional oncology.
12 Apr 2016
Treating cancer that began in the liver or has spread to the liver can often involve months of chemotherapy and painful radiation treatments. But now there’s a new procedure that takes tiny beads that carry a high dose of radiation and sends them straight to the cancer.
5 Apr 2016
BTG plc (LSE: BTG), a global specialist healthcare company, has today announced the publication of a new medtech innovation briefing (MIB) by NICE (National Institute for Health and Care Excellence) for TheraSphere yttrium-90 glass microsphere therapy.1
30 Mar 2016
Imagine an exquisitely precise cancer therapy procedure done through a small opening in the body
7 Jan 2016
PATIENT PERSPECTIVE When Eleanor Cook’s cancer spread to her liver, it was a sign that something in her treatment regimen had to change.
The announced $160 billion merger between Pfizer and Allergan in November was a fitting cap to a year of frenzied deal-making in pharmaceuticals and life sciences.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com